fda import alert 66-80 glp-1 green list Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide US FDA creates 'green list'

C.GomesR.LaterraJ

This ensures controlled dosage and maximum efficacy but requires clinic visits and higher costs

Test the final solution/serum with pH strips before use

The question of lifelong GLP-1 therapy does not have a universal answer, as treatment duration depends on the indication, individual patient circumstances, and treatment goals

This aligns with findings from SURPASS-CVOT, which showed no meaningful additive effect on MACE compared to an older GLP-1 receptor agonist, and with findings of a potential greater protection in heart failure that could be compatible with more pronounced weight loss mediated by GIP 16,22